News & Articles

New system provides end-to-end solution for researchers to validate specificity of CRISPR and other genome editing projects

The collaboration aims to advance the scale-up of hMSC manufacturing for regenerative medicine

Developed in partnership with Rosetta Biosciences, discovery enables simultaneous detection of multiple targets, furthering next generation of diagnostics

Discover how researchers are harnessing novel slide-scanning technology to improve the understanding of regenerative biology

Discover the impact of base editing technology and learn how to introduce it into your cell therapy pipeline

Watch this on-demand webinar to learn more about manipulating the genes within physiologically relevant human immune cells

Learn how the latest proteomics technology is driving large-scale, high-throughput studies in disease biology

Parties to collaborate on development, commercialization, and supply of the Orgenesis therapies pipeline

Addition of CRISPR and RNAi offerings to complement PerkinElmer's life sciences and applied genomics solutions, with future opportunities to improve cell based discovery for precision medicine

From Alzheimer’s disease to 3D brain modeling: Watch top speakers and connect with leading neuroscience innovators online, November 17-18

Join us Monday, November 16, to explore the advantages and applications of direct molecular testing

Which new products made the most difference to your lab work this year?

The study leverages the Tapestri Platform to illustrate the single-cell atlas of acute myeloid leukemia (AML) with multi-omics, describing the clonality underlying therapeutic resistance

Proven, scalable platform aims to increase dose yields and reduces process development time for cell and gene therapies

Watch world-renowned experts and connect with leading innovators on the hottest topics, new developments and latest technologies in neuroscience

Join us Thursday, November 5, to learn how to introduce base editing technology into your cell therapy pipeline

The Phase II clinical trial, which will use cutting-edge CRISPR genetic engineering, has already begun enrolling patients